<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title>cetuximab</title><link>http://www.unboundmedicine.com/medline/ebm/research/cetuximab</link><description>Unbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.</description><language>en-us</language><copyright>Unbound Medicine, Inc.</copyright><item><title>Altered fractionation and adjuvant chemotherapy for head and neck squamous cell carcinoma.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19894219/full_citation/Altered_fractionation_and_adjuvant_chemotherapy_for_head_and_neck_squamous_cell_carcinoma_</link><description>Mendenhall WM, Riggs CE, Vaysberg M, et al. <br/><span class="title">Altered fractionation and adjuvant chemotherapy for head and neck squamous cell carcinoma. [JOURNAL ARTICLE]</span><br/><span class="source" title="Head &amp; neck">Head Neck 2009 Nov 5.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19894219/abstract/Altered_fractionation_and_adjuvant_chemotherapy_for_head_and_neck_squamous_cell_carcinoma_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19894219/full_citation/Altered_fractionation_and_adjuvant_chemotherapy_for_head_and_neck_squamous_cell_carcinoma_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19894219/Altered_fractionation_and_adjuvant_chemotherapy_for_head_and_neck_squamous_cell_carcinoma_">Find Related Articles</a> </description></item><item><title>The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19892771/full_citation/The_Role_of_EGFR_Inhibition_in_the_Treatment_of_Non_Small_Cell_Lung_Cancer_</link><description>Ray M, Salgia R, Vokes EE <br/><span class="title">The Role of EGFR Inhibition in the Treatment of Non-Small Cell Lung Cancer. [JOURNAL ARTICLE]</span><br/><span class="source" title="The oncologist">Oncologist 2009 Nov 5.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19892771/abstract/The_Role_of_EGFR_Inhibition_in_the_Treatment_of_Non_Small_Cell_Lung_Cancer_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19892771/full_citation/The_Role_of_EGFR_Inhibition_in_the_Treatment_of_Non_Small_Cell_Lung_Cancer_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19892771/The_Role_of_EGFR_Inhibition_in_the_Treatment_of_Non_Small_Cell_Lung_Cancer_">Find Related Articles</a> </description></item><item><title>Docetaxel: its role in current and future treatments for advanced gastric cancer.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19890692/full_citation/Docetaxel:_its_role_in_current_and_future_treatments_for_advanced_gastric_cancer_</link><description>Nishiyama M, Wada S <br/><span class="title">Docetaxel: its role in current and future treatments for advanced gastric cancer. [Journal Article]</span><br/><span class="source" title="Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association">Gastric Cancer 2009; 12(3):132-41.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19890692/abstract/Docetaxel:_its_role_in_current_and_future_treatments_for_advanced_gastric_cancer_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19890692/full_citation/Docetaxel:_its_role_in_current_and_future_treatments_for_advanced_gastric_cancer_">Full Citation</a></description></item><item><title>Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19889608/full_citation/Combined_cetuximab_and_trastuzumab_are_superior_to_gemcitabine_in_the_treatment_of_human_pancreatic_carcinoma_xenografts_</link><description>Larbouret C, Robert B, Bascoul-Mollevi C, et al. <br/><span class="title">Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts. [JOURNAL ARTICLE]</span><br/><span class="source" title="Annals of oncology : official journal of the European Society for Medical Oncology / ESMO">Ann Oncol 2009 Nov 4.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19889608/abstract/Combined_cetuximab_and_trastuzumab_are_superior_to_gemcitabine_in_the_treatment_of_human_pancreatic_carcinoma_xenografts_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19889608/full_citation/Combined_cetuximab_and_trastuzumab_are_superior_to_gemcitabine_in_the_treatment_of_human_pancreatic_carcinoma_xenografts_">Full Citation</a> | <a href="http://annonc.oxfordjournals.org/cgi/pmidlookup%3fview=long%26amp;pmid=19889608">Publisher Full Text</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19889608/Combined_cetuximab_and_trastuzumab_are_superior_to_gemcitabine_in_the_treatment_of_human_pancreatic_carcinoma_xenografts_">Find Related Articles</a> </description></item><item><title>Weekly cetuximab and gemcitabine plus cisplatin as salvage therapy for unresectable non-small cell lung cancer.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19887875/full_citation/Weekly_cetuximab_and_gemcitabine_plus_cisplatin_as_salvage_therapy_for_unresectable_non_small_cell_lung_cancer_</link><description>Tai CJ, Hsu CH, Wang FJ, et al. <br/><span class="title">Weekly cetuximab and gemcitabine plus cisplatin as salvage therapy for unresectable non-small cell lung cancer. [Letter]</span><br/><span class="source" title="Onkologie">Onkologie 2009 Nov; 32(11):685-6.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19887875/full_citation/Weekly_cetuximab_and_gemcitabine_plus_cisplatin_as_salvage_therapy_for_unresectable_non_small_cell_lung_cancer_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19887875/Weekly_cetuximab_and_gemcitabine_plus_cisplatin_as_salvage_therapy_for_unresectable_non_small_cell_lung_cancer_">Find Related Articles</a> </description></item><item><title>Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19884556/full_citation/Analysis_of_PTEN_BRAF_and_EGFR_Status_in_Determining_Benefit_From_Cetuximab_Therapy_in_Wild_Type_KRAS_Metastatic_Colon_Cancer_</link><description>Laurent-Puig P, Cayre A, Manceau G, et al. <br/><span class="title">Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer. [JOURNAL ARTICLE]</span><br/><span class="source" title="Journal of clinical oncology : official journal of the American Society of Clinical Oncology">J Clin Oncol 2009 Nov 2.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19884556/abstract/Analysis_of_PTEN_BRAF_and_EGFR_Status_in_Determining_Benefit_From_Cetuximab_Therapy_in_Wild_Type_KRAS_Metastatic_Colon_Cancer_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19884556/full_citation/Analysis_of_PTEN_BRAF_and_EGFR_Status_in_Determining_Benefit_From_Cetuximab_Therapy_in_Wild_Type_KRAS_Metastatic_Colon_Cancer_">Full Citation</a> | <a href="http://www.jco.org/cgi/pmidlookup%3fview=long%26amp;pmid=19884556">Publisher Full Text</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19884556/Analysis_of_PTEN_BRAF_and_EGFR_Status_in_Determining_Benefit_From_Cetuximab_Therapy_in_Wild_Type_KRAS_Metastatic_Colon_Cancer_">Find Related Articles</a> </description></item><item><title>A Wortmannin-Cetuximab as a Double Drug.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19883074/full_citation/A_Wortmannin_Cetuximab_as_a_Double_Drug_</link><description>Smith RA, Yuan H, Weissleder R, et al. <br/><span class="title">A Wortmannin-Cetuximab as a Double Drug. [JOURNAL ARTICLE]</span><br/><span class="source" title="Bioconjugate chemistry">Bioconjug Chem 2009 Nov 2.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19883074/abstract/A_Wortmannin_Cetuximab_as_a_Double_Drug_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19883074/full_citation/A_Wortmannin_Cetuximab_as_a_Double_Drug_">Full Citation</a></description></item><item><title>Hepatic Toxicities Associated with the Use of Preoperative Systemic Therapy in Patients with Metastatic Colorectal Adenocarcinoma to the Liver.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19880627/full_citation/Hepatic_Toxicities_Associated_with_the_Use_of_Preoperative_Systemic_Therapy_in_Patients_with_Metastatic_Colorectal_Adenocarcinoma_to_the_Liver_</link><description>Cleary JM, Tanabe KT, Lauwers GY, et al. <br/><span class="title">Hepatic Toxicities Associated with the Use of Preoperative Systemic Therapy in Patients with Metastatic Colorectal Adenocarcinoma to the Liver. [JOURNAL ARTICLE]</span><br/><span class="source" title="The oncologist">Oncologist 2009 Oct 30.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19880627/abstract/Hepatic_Toxicities_Associated_with_the_Use_of_Preoperative_Systemic_Therapy_in_Patients_with_Metastatic_Colorectal_Adenocarcinoma_to_the_Liver_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19880627/full_citation/Hepatic_Toxicities_Associated_with_the_Use_of_Preoperative_Systemic_Therapy_in_Patients_with_Metastatic_Colorectal_Adenocarcinoma_to_the_Liver_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19880627/Hepatic_Toxicities_Associated_with_the_Use_of_Preoperative_Systemic_Therapy_in_Patients_with_Metastatic_Colorectal_Adenocarcinoma_to_the_Liver_">Find Related Articles</a> </description></item><item><title>Cetuximab and panitumumab: are they interchangeable?</title><link>http://www.unboundmedicine.com/medline/ebm/record/19875336/full_citation/Cetuximab_and_panitumumab:_are_they_interchangeable</link><description>Kim R <br/><span class="title">Cetuximab and panitumumab: are they interchangeable? [LETTER]</span><br/><span class="source" title="The lancet oncology">Lancet Oncol 2009 Oct 27.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19875336/full_citation/Cetuximab_and_panitumumab:_are_they_interchangeable">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19875336/Cetuximab_and_panitumumab:_are_they_interchangeable">Find Related Articles</a> </description></item><item><title>MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer.</title><link>http://www.unboundmedicine.com/medline/ebm/record/19862647/full_citation/MDR1_polymorphism_role_in_patients_treated_with_cetuximab_and_irinotecan_in_irinotecan_refractory_colorectal_cancer_</link><description>Paule B, Castagne V, Picard V, et al. <br/><span class="title">MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. [JOURNAL ARTICLE]</span><br/><span class="source" title="Medical oncology (Northwood, London, England)">Med Oncol 2009 Oct 28.</span><br/> <a href="http://www.unboundmedicine.com/medline/ebm/record/19862647/abstract/MDR1_polymorphism_role_in_patients_treated_with_cetuximab_and_irinotecan_in_irinotecan_refractory_colorectal_cancer_">Abstract</a> | <a href="http://www.unboundmedicine.com/medline/ebm/record/19862647/full_citation/MDR1_polymorphism_role_in_patients_treated_with_cetuximab_and_irinotecan_in_irinotecan_refractory_colorectal_cancer_">Full Citation</a> | <a rel="nofollow" href="http://www.unboundmedicine.com/medline/ebm/related/19862647/MDR1_polymorphism_role_in_patients_treated_with_cetuximab_and_irinotecan_in_irinotecan_refractory_colorectal_cancer_">Find Related Articles</a> </description></item></channel></rss>